2026-07-23T23:01:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/230962024-11-29T23:54:16Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Horgan, Denis author Van den Bulcke, Marc author Malapelle, Umberto author Troncone, Giancarlo author Normanno, Nicola author Capoluongo, Ettore D author Prelaj, Arsela author Rizzari, Carmelo author Trapani, Dario author Singh, Jaya author Kozaric, Marta author Longshore, John author Ottaviano, Manuel author Boccia, Stefania author Pravettoni, Gabriella author Cattaneo, Ivana author Malats, Nuria author Buettner, Reinhard author Lekadir, Karim author de Lorenzo, Francesco author Hofman, Paul author De Maria, Ruggero author 2024-01-15 Next-generation sequencing (NGS) and liquid biopsy (LB) showed positive results in the fight against different cancer types. This paper aims to assess the uptake of advanced molecular diagnostics/NGS for quick and efficient genetic profiles of tumour cells. For that purpose, the European Alliance for Personalised Medicine conducted a series of expert interviews to ascertain the current status across member states. One stakeholder meeting was additionally conducted to prioritize relevant factors by stakeholders. Seven common pillars were identified, and twenty-five measures were defined based on these pillars. Results showed that a multi-faceted approach is necessary for successful NGS implementation and that regional differences may be influenced by healthcare policies, resources, and infrastructure. It is important to consider different correlations when interpreting the results and to use them as a starting point for further discussion. Heliyon . 2023 ;10(1):e23914 10.1016/j.heliyon.2023.e23914 2405-8440 Heliyon 38234913 https://hdl.handle.net/20.500.12105/23096 Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems.